Business Wire

CSG Cloud-Native Rating and Charging Solution Now in Production With Customers Worldwide

29.4.2020 15:00:00 EEST | Business Wire | Press release

Share

CSG ® (NASDAQ: CSGS) today introduced a new addition to its Ascendon platform, CSG Ascendon Rating & Charging, a fully cloud-native, serverless charging software as a service (SaaS). Now actively in use, the solution provides CSG customers with real-time online charging functionality and rating capabilities to support and scale for wireless and digital services offered today and in the future.

As device types and connections surge, operators need highly flexible solutions to rate and charge for events in real-time, at scale, and for innovative monetization models. As a fully hosted, multi-tenant, SaaS solution architected on Amazon Web Services (AWS), Ascendon Rating and Charging elastically scales when volumes fluctuate allowing for efficient and cost-effective management of network resources.

The solution can be used to configure any combination of products, offers, and eligibility rules, as well as how they are sold across channels, in a matter of minutes. It enables balance sharing across multiple devices and services and gives operators the ability to charge dynamically based on network events, with real-time notifications to help engage the customer.

The solution also provides online charging system (OCS) capabilities including real-time authorization and balance management for voice, data, content and digital services; usage processing and rating; and dynamic entitlements that ensure accurate charging.

“Modern business models are centered around emerging digital offers that can be deployed quickly and cost effectively,” said Chad Dunavant, head of global product management, CSG. “CSG Ascendon Rating and Charging is a new breed of cloud-native SaaS that helps operators successfully deploy new services like 5G, while helping them manage risk and optimize operational costs.” (video)

Key technical features include:

  • Resiliency by design: High availability and geographically distributed across multiple AWS availability zones (AZs) to help ensure a fail-proof environment. It exceeds the resilience of traditional data centers by utilizing multiple AZs by design, providing a minimum of active-active-active configuration.
  • Grow as you go: Provides an unlimited supply of cloud-compute and scalability through AWS, taking the guesswork out of required capacity and eliminating the need for large upfront capital expenditures, lowering operational costs.
  • Fully featured and highly flexible: Configurable to support any wireless or digital service or bundled offer, as well as multiple charging models including pre-pay, post-pay, currency conversion, payments, invoicing, and adjustments.
  • Fully managed: Complete management of operations and issues, as well as automated quarterly releases deployed by CSG, allowing for rapid deployment of new features and efficient management of resources internally.
  • Network/platform agnostic: Charge for any transaction across any network or service platform.

This solution is part of CSG Ascendon, a globally recognized and award-winning digital monetization platform that has helped some of the world’s most innovative companies not just compete but thrive in the digital economy. Ascendon is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities that support more than 500 companies globally, providing them with flexible and configurable technology solutions that help them monetize and digitally enable their customer experiences.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com

David Banks
Investor Relations
CSG
+1 (303) 200-3127
david.banks@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye